Welcome to our dedicated page for Exact Sciences SEC filings (Ticker: EXAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exact Sciences Corp (NASDAQ: EXAS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Exact Sciences’ cancer screening and diagnostic testing business, financial performance, and significant corporate events.
For EXAS, key filings include current reports on Form 8-K that describe material developments. One Form 8-K reports quarterly financial results, including revenue contributions from the Screening grouping, which encompasses Cologuard tests and PreventionGenetics, and from the Precision Oncology grouping, which includes global Oncotype DX and therapy selection tests. These filings also discuss non‑GAAP metrics such as adjusted EBITDA, adjusted gross margin, and free cash flow, along with reconciliations and management’s rationale for using these measures.
Another important 8-K details the Agreement and Plan of Merger among Exact Sciences, Abbott Laboratories, and a wholly owned Abbott subsidiary. This filing explains the structure of the proposed merger, the per‑share cash consideration to be paid for Exact Sciences common stock, the treatment of equity awards, the conditions to closing, termination rights, and any potential termination fee. It also notes that Exact Sciences’ board of directors unanimously approved the merger agreement and recommends that stockholders adopt it, subject to customary conditions.
Additional 8-K filings describe a collaboration and license agreement with Freenome Holdings, Inc. for blood‑based colorectal cancer screening tests, as well as other corporate announcements furnished as exhibits, such as earnings press releases and investor communications. These documents provide context on how Exact Sciences is expanding its portfolio in blood‑based screening and multi‑cancer early detection.
On Stock Titan, investors can review these SEC filings as they are made available through EDGAR. AI‑powered tools can help summarize lengthy disclosures, highlight key terms of material agreements, and surface notable changes in guidance, capital structure, or strategic direction, enabling users to quickly understand the implications of new EXAS filings.
Exact Sciences President and CEO Kevin T. Conroy reported multiple equity compensation events involving restricted stock units and common stock. On February 27, 2026, several restricted stock unit awards vested, each unit representing a right to receive one share of common stock.
Upon vesting, Mr. Conroy acquired corresponding shares of common stock through derivative exercises, and the company retained blocks of 8,528, 10,419, and 13,060 shares at $103.25 per share for tax withholding purposes. After these transactions, he directly held 1,278,045 shares in various accounts and plans, plus additional indirect holdings.
A footnote states that, in addition to the common shares reported, Mr. Conroy also holds an aggregate of 737,129 vested and unvested options and restricted stock units, each unit representing a contingent right to receive one share of common stock.
Exact Sciences EVP of Human Resources Sarah Condella reported several equity transactions in company stock. She exercised stock options covering 3,900 shares of Common Stock at an exercise price of $5.03 per share, increasing her direct holdings before related tax withholding.
To cover tax obligations from this option exercise, 1,913 shares of Common Stock were retained by Exact Sciences at $103.38 per share, leaving her with 131,121 shares held directly and 6,368 shares held indirectly in a 401(k) plan. Footnotes note that the Form 4 covers 137,489 shares of Common Stock in total and that she also holds an additional 71,243 vested and unvested options and restricted stock units.
Condella Sarah reported acquisition or exercise transactions in this Form 4 filing.
EXACT Sciences executive Sarah Condella received an equity award in the form of restricted stock units. On February 25, 2026, the EVP of Human Resources was granted 23,224 restricted stock units at a price of $0.00 per unit.
Each restricted stock unit represents a contingent right to receive one share of common stock and will vest in four equal annual installments beginning on February 25, 2027. After this award, she holds 135,489 shares of common stock (including 129,134 shares held directly and 6,355 shares held indirectly in a 401(k) plan), and in addition holds 75,143 vested and unvested options and restricted stock units.
Herriott James reported acquisition or exercise transactions in this Form 4 filing.
Exact Sciences Corp reported that SVP, General Counsel & Secretary James Herriott received a grant of 20,321 restricted stock units (RSUs) on February 25, 2026. Each RSU represents a contingent right to receive one share of common stock and carries no purchase price.
These RSUs vest in four equal annual installments beginning on February 25, 2027. After this award, Herriott holds a total of 69,577 shares of common stock (including shares held directly and in a 401(k) plan), and in addition holds an aggregate of 23,975 vested and unvested options and restricted stock units tied to Exact Sciences common stock.
EXACT SCIENCES CORP President and CEO Kevin T. Conroy reported multiple equity compensation transactions. On February 25, 2026, he was granted 154,829 restricted stock units, each representing a contingent right to receive one share of common stock, and received an additional 13,181 shares of common stock upon vesting of a restricted stock unit award.
On the same date, 6,196 shares of common stock were disposed of at $103.45 per share to satisfy tax withholding obligations in connection with the net-settlement of vested restricted stock units. A related footnote states these restricted stock units vest in four equal annual installments beginning on February 25, 2027. The filing also notes that, beyond the 1,521,721 shares of common stock reported, Mr. Conroy holds an additional 805,226 vested and unvested options and restricted stock units.
Baranick Brian reported acquisition or exercise transactions in this Form 4 filing.
EXACT SCIENCES CORP executive Brian Baranick received an equity award in the form of restricted stock units. On February 25, 2026, he was granted 28,063 restricted stock units, each representing a contingent right to receive one share of common stock at no purchase price.
These restricted stock units vest in four equal annual installments beginning on February 25, 2027, tying the award to multi‑year service. Following this grant, Baranick holds 103,874 shares of common stock directly, 795 shares indirectly through a 401(k) plan, and in aggregate an additional 28,063 restricted stock units.
ORVILLE JACOB A reported acquisition or exercise transactions in this Form 4 filing.
EXACT SCIENCES CORP EVP Jacob A. Orville received an equity award of 38,707 restricted stock units on February 25, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in four equal annual installments beginning on February 25, 2027.
After this grant, Mr. Orville directly holds 100,403 shares of common stock and indirectly holds 1,759 shares through a 401(k) plan, for a total of 102,162 shares reported. He also holds, in the aggregate, an additional 45,288 vested and unvested options and restricted stock units.
Bloomer Aaron reported acquisition or exercise transactions in this Form 4 filing.
Exact Sciences EVP and CFO Aaron Bloomer received an equity award of 28,063 restricted stock units. Each unit represents a contingent right to receive one share of common stock at no purchase price.
These restricted stock units vest in four equal annual installments beginning on February 25, 2027. After this award, Bloomer directly holds 48,768 shares of common stock and an additional 417 shares are held indirectly in a 401(k) plan, totaling 49,185 shares. He also holds, in the aggregate, 32,458 restricted stock units.
Exact Sciences Corporation reported the results of a special shareholder meeting held to vote on its planned merger with Abbott Laboratories. Stockholders holding 128,906,310 shares, or 67.56% of shares entitled to vote as of the January 9, 2026 record date, were present, constituting a quorum.
Stockholders voted 128,431,562 shares for, 386,941 against, and 87,807 abstaining to adopt the Merger Agreement, effectively approving the merger with Abbott. An advisory proposal on merger-related executive compensation received 42,290,727 votes for and 85,655,344 against, so it was not approved. A proposal to permit adjournment of the meeting, if necessary, received 123,806,529 votes for and 4,845,599 against, and was approved. Completion of the merger remains subject to customary closing conditions, including required regulatory approvals.
Exact Sciences Corp. received an updated ownership report from Capital World Investors, a division of Capital Research and Management Company and its affiliates. Capital World Investors is deemed to beneficially own 968,232 shares of Exact Sciences common stock, representing 0.5% of the 189,916,880 shares believed to be outstanding as of the reporting date.
The filing states that Capital World Investors has sole voting power over 968,142 shares and sole dispositive power over 968,232 shares, with no shared voting or dispositive power. It also certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Exact Sciences.